TY - JOUR
T1 - Towards a 21st-century roadmap for biomedical research and drug discovery
T2 - consensus report and recommendations
AU - Langley, Gillian R.
AU - Adcock, Ian M.
AU - Busquet, François
AU - Crofton, Kevin M.
AU - Csernok, Elena
AU - Giese, Christoph
AU - Heinonen, Tuula
AU - Herrmann, Kathrin
AU - Hofmann-Apitius, Martin
AU - Landesmann, Brigitte
AU - Marshall, Lindsay J.
AU - Mcivor, Emily
AU - Muotri, Alysson R.
AU - Noor, Fozia
AU - Schutte, Katrin
AU - Seidle, Troy
AU - van de Stolpe, Anja
AU - van Esch, Hilde
AU - Willett, Catherine
AU - Woszczek, Grzegorz
N1 - © 2016, Elsevier. Licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/
PY - 2017/2
Y1 - 2017/2
N2 - Decades of costly failures in translating drug candidates from preclinical disease models to human therapeutic use warrant reconsideration of the priority placed on animal models in biomedical research. Following an international workshop attended by experts from academia, government institutions, research funding bodies, and the corporate and nongovernmental organisation (NGO) sectors, in this consensus report, we analyse, as case studies, five disease areas with major unmet needs for new treatments. In view of the scientifically driven transition towards a human pathway-based paradigm in toxicology, a similar paradigm shift appears to be justified in biomedical research. There is a pressing need for an approach that strategically implements advanced, human biology-based models and tools to understand disease pathways at multiple biological scales. We present recommendations to help achieve this.
AB - Decades of costly failures in translating drug candidates from preclinical disease models to human therapeutic use warrant reconsideration of the priority placed on animal models in biomedical research. Following an international workshop attended by experts from academia, government institutions, research funding bodies, and the corporate and nongovernmental organisation (NGO) sectors, in this consensus report, we analyse, as case studies, five disease areas with major unmet needs for new treatments. In view of the scientifically driven transition towards a human pathway-based paradigm in toxicology, a similar paradigm shift appears to be justified in biomedical research. There is a pressing need for an approach that strategically implements advanced, human biology-based models and tools to understand disease pathways at multiple biological scales. We present recommendations to help achieve this.
KW - biomedical research
KW - research funding
KW - adverse outcome pathways
KW - 21st-century roadmap
KW - human-specific models
KW - human disease pathways
UR - http://www.scopus.com/inward/record.url?scp=85006176599&partnerID=8YFLogxK
U2 - 10.1016/j.drudis.2016.10.011
DO - 10.1016/j.drudis.2016.10.011
M3 - Article
SN - 1359-6446
VL - 22
SP - 327
EP - 339
JO - Drug Discovery Today
JF - Drug Discovery Today
IS - 2
ER -